fluticasone furoate/vilanterol (Breo Ellipta )


Original post, click here

Generic Name: fluticasone furoate/vilanterol

Brand Name: Breo Ellipta

Manufacturer: GlaxoSmithKline Inc.

Indications: Asthma

Manufacturer Requested Reimbursement Criteria1:

After considering the new data from a pragmatic randomized controlled trial representative of everyday clinical practice, Breo Ellipta is clinically more effective and cost-effective at improving asthma control than usual care, which included Advair:

Breo Ellipta should be reimbursed preferentially to Advair to maximize asthma control.

Submission Type: Resubmission 2

Project Status: Pending

Call For Patient Input: April 4, 2018

Patient Input Closed: May 24, 2018

Anticipated Date: May 2, 2018

Biosimilar: No

Fee Schedule: Pending

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Submit Feedback

Tags

asthma, respiratory